- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Access Advocacy for BTK Inhibitors
A panel of specialists discuss patient access advocacy for BTK inhibitors.
EP: 1.Recent Trends and Innovations in the Management of CLL
EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors
EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment
EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy
EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence
EP: 6.Optimizing Therapy Sequencing in CLL
EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
EP: 8.Decision-Making in CLL: The Role of Real-World Evidence
EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL
EP: 13.Patient Access Advocacy for BTK Inhibitors
EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Video content above is prompted by the following:
- How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
- What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?
Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World
November 9th 2024The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton tyrosine kinase inhibitor treatment 6 months after the fixed-duration period.
Read More
KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment
November 6th 2024These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ex vivo expansion needed for NK cell–based therapies, such as chimeric antigen receptor–NK cell treatment.
Read More
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL
October 17th 2024The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.
Read More
